Women live longer on average than men. But they also spend 25% more of their lives in poor health—nine years more. And mostly during their working years, not in old age. Here you’ll learn what this figure means, what lies behind it, and what research says about how it can be changed.
The figure that has shaped the debate on women’s health since its publication at the World Economic Forum in Davos in January 2024 is this: Women spend 25% more of their lives in poor health than men.
The study was conducted by the McKinsey Health Institute in collaboration with the World Economic Forum. It was the first time the extent of the so-called gender health gap had been quantified globally with such precision.
Women live longer on average than men. For a long time, this was taken as evidence that women are healthier or that the healthcare system provides them with adequate care. The 25-percent figure completely dispels this assumption.
Living longer is not the same as living well. Women spend a disproportionate part of their longer lives in poor health, with limitations, and with chronic conditions that the healthcare system has consistently failed to prevent, detect, or treat.
This gap corresponds to 75 million years of life lost every year to poor health or premature death. Closing it would give every woman in the world seven additional healthy days per year—more than 500 days over the course of a lifetime. And it would grow the global economy by more than a trillion dollars annually by 2040.
These are not wishful projections. They are the documented economic costs of what is already happening, measured in healthy years of life that women do not get.
Nine years, and mostly during working years
The average woman spends nine years more than the average man in poor health or with some form of limitation.
This figure is made even more striking by another finding: About half of the healthy years women lose occur between the ages of 20 and 60.
This is not illness in old age. This is chronic suffering during the very decades in which women build careers, raise families, run businesses, and make the majority of health decisions for everyone around them. These are the years of peak productivity, greatest ambitions, and most responsibility that are lost.
The conditions behind this are neither rare nor biologically mysterious. They are conditions that affect hundreds of millions of women, have been documented for decades, and have received only a fraction of the research funding that their prevalence would warrant.
PMS, endometriosis, menopause, migraines, pregnancy- and childbirth-related conditions, and cardiovascular diseases in women: These nine conditions alone account for a third of the total health gap.
PMS and menopause together—conditions that affect virtually every woman who reaches middle age—received less than 1% of the research funding allocated to the conditions behind this gap between 2019 and 2023.
What the doctors said when they finally got a major platform
In October 2025, the episode of The Diary of a CEO with Dr. Mary Claire Haver, Dr. Vonda Wright, Dr. Stacy Sims, and Dr. Natalie Crawford became one of the most-shared conversations about women’s health that the media had ever produced.
What the doctors described was not a new discovery. It was a long-documented reality that had finally been spoken aloud on a stage large enough to reach those affected.
Women come to the doctor’s office with serious symptoms and are told that it is stress, anxiety, or simply part of being a woman. Women with endometriosis wait an average of six to ten years for a diagnosis because their pain is normalized instead of investigated. And women in perimenopause enter one of the most physically profound transitions of their lives—without preparation or support, because the medical system has never developed suitable tools for this phase.
Dr. Wright described this as “Whiny Woman Syndrome,” the well-documented pattern of attributing women’s symptoms to emotional rather than biological causes. The result is delayed diagnoses, inadequately treated pain, and years of suffering that could have been addressed sooner if the symptoms had been taken as seriously as they would be in a male patient.
This is not an isolated observation. It is a pattern so well-documented that it has a name. And the women who have experienced it recognize the description immediately.
Women with very serious conditions get lost in the healthcare system for years. Sometimes they are told that it is all in their heads, when in fact they are seriously ill.
The three causes identified by the WEF and McKinsey
The McKinsey Health Institute report identifies three structural causes of the health gap that apply across all conditions and regions of the world.
The first is a gap in science itself. Female biology is insufficiently researched, women have historically been underrepresented in clinical trials, and the data underpinning treatment decisions is disproportionately based on male data.
The second is a gap in care. Even where knowledge exists, it is not consistently applied. Women face greater barriers to accessing treatment, and their symptoms are more often dismissed or inadequately treated.
The third is a data gap. There are fewer standardized measurement tools for conditions affecting women. They are less often included in large epidemiological studies. And therefore, the evidence that would spur investment and policy changes is less often generated.
These three gaps reinforce one another. Inadequate science produces inadequate care. Inadequate care produces inadequate data. And inadequate data provides no arguments for better science.
This cycle has been going on for decades. Its result is the 25-percent figure: 25% more time spent in poor health due to conditions that could be avoided or treated, or at least better understood than the current system has allowed.
The cellular level that rarely appears in the debate
The public discussion about the health gap focuses primarily on research funding, clinical bias, and the absence of women in studies. All of this is real and important.
What almost never appears is the cellular level: the fact that the fundamental biological processes that maintain women’s health receive less and less support with age, specifically due to the decline of NAD⁺.
NAD⁺ is behind energy production, DNA repair, hormone production, sleep regulation, immune function, and inflammation control. In every adult, its levels drop by the mid-20s. By middle age, they are only about half of their peak.
In women, this decline occurs in parallel with the hormonal changes of perimenopause and menopause. Both processes amplify their impact on health and performance.
The enzyme that produces progesterone needs NAD⁺ as a cofactor. Sirtuins, which regulate inflammation, need NAD⁺ for activation. And mitochondria, which supply energy to all the tissues that change during menopause, need NAD⁺ to produce energy efficiently.
The cellular energy deficiency caused by the decline in NAD⁺ cannot be viewed separately from the health gap. It is one of the underlying biological mechanisms, and it operates on a level that most clinical debates about women’s health have never looked at.
The health gap in women is a failure of research and a failure of funding. But it is also a failure of cellular energy supply, and policy alone cannot solve that.
What would be needed to close the gap
The action plan published by McKinsey and the World Economic Forum in January 2025 identifies what would be structurally necessary: more research specifically on female biology, better sex-disaggregated data, clinical guidelines that reflect the female course of disease, and investments directed where the disease burden is highest and research funding has been lowest to date.
The Gates Foundation has pledged $2.5 billion for this by 2030. The World Economic Forum has established the Global Alliance for Women’s Health with more than 120 member organizations. And every dollar invested in women’s health is estimated to return around three dollars in economic growth.
On an individual level, closing the gap means that women get access to information about their own biology that the current system has not reliably provided them. This includes the cellular mechanisms behind their symptoms, the existing research on them, and products that were actually developed based on their biology, not as an afterthought.
NMN is one of the few longevity interventions whose foundational human study was specifically conducted with women and measured results that are directly relevant to female metabolic health.
This level of precision is not the norm. It is what it concretely means to take biology seriously. And it is the minimum standard that women have always deserved.
The seven days that matter
Closing the health gap would give every woman in the world seven additional healthy days per year. On its own, that sounds like little. Over a lifetime, it is 500 days. And for over 3.9 billion women, it would mean 75 million healthy years of life regained every year—for conditions that are already understood, already partially treatable, and chronically underfunded.
The 25-percent figure is not a law of nature. It is the documented price of decisions that a healthcare system and a research industry have made over decades. And it can be reversed by making different decisions. The momentum for this—in funding, research, and public debate—has never been greater than it is now.
Women live longer. But they also spend more of those years in poor health than they should, and lose the most productive decades of their lives to conditions that have never been sufficiently researched, sufficiently funded, or sufficiently taken seriously.
That is the 25-percent figure. A figure that should not exist and that a growing international alliance of researchers, doctors, and institutions is now trying to change. The question for every woman who reads this is what she does in the meantime while the system catches up with the biology it has overlooked for so long.
Sources
- McKinsey Health Institute & World Economic Forum. (2024). Closing the women's health gap: A $1 trillion opportunity to improve lives and economies. https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies
- McKinsey Health Institute & World Economic Forum. (2025). Blueprint to close the women's health gap: How to improve lives and economies for all. https://www.mckinsey.com/mhi/our-insights/blueprint-to-close-the-womens-health-gap
- McKinsey Health Institute. (2024, January 30). MHI unveils investment case for closing the women's health gap. https://www.mckinsey.com/about-us/new-at-mckinsey-blog/mhi-unveils-investment-case-for-closing-the-womens-health-gap
- Gates Foundation. (2025). Gates Foundation announces catalytic funding for women-centered research. https://www.gatesfoundation.org/ideas/media-center/press-releases/2025/08/womens-health-funding-commitment
- Haver, M. C., Wright, V., Sims, S., & Crawford, N. (2025, October 16). Hormone & fertility experts: We've been lied to about women's health. The Diary of a CEO with Steven Bartlett.
- World Economic Forum. (2025, January). There's a women's health gap: Here's how to close it. https://www.weforum.org/stories/2025/01/theres-a-womens-health-gap-heres-how-to-close-it/
- Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. https://doi.org/10.1126/science.abe9985
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141.
